Plural Oxygens Patents (Class 514/718)
-
Publication number: 20120208767Abstract: A method includes obtaining a biological sample from a subject that does not display a symptom of Painful Bladder Syndrome (PBS). The method also includes analyzing the biological sample for a mutated form of NAD(P)H dehydrogenase [quinone], also known as Quinone Oxidoreductase 1, abbreviated NQO1, or a mutation of a NQO1 gene. The method also includes determining a risk of PBS for the subject based on analyzing the biological sample. In some methods, the mutation determined to present an increased risk is a cytosine to thymine nucleotide substitution at a position that leads to a proline to serine amino acid substitution at amino acid position 187 to produce a protein NQO1P187S. Another method includes selecting a subject that has above normal risk of Painful Bladder Syndrome (PBS) or is expressing a symptom of PBS, and treating the subject with a therapeutically effective amount of an antioxidant.Type: ApplicationFiled: February 14, 2012Publication date: August 16, 2012Applicant: University of Maryland, BaltimoreInventor: Anil K. Jaiswal
-
Publication number: 20120201887Abstract: A pharmaceutical composition in the form of a tablet including a first portion and a second portion, wherein said first portion includes guaifenesin having an immediate release profile and a second drug having a sustained release profile, and wherein the second portion includes guaifenesin having a sustained release profile. The second drug can be in the form of a drug-resin complex. The second drug can be either an anti-tussive or a decongestant. The drug-resin complex includes a drug complexed to an ion exchange resin. The ion exchange resin can be a polystyrene sulfonate resin, polacrilex resin, polacrilin potassium, cholestyramine resin, or a colestyramine resin. The drug-resin complex can be provided with a coating, the coating thickness being selected to obtain the desired release profile. The drug-resin complex can be provided with a coating level of from 5% to 50%. The coating level can be from 10% to 35%.Type: ApplicationFiled: February 4, 2011Publication date: August 9, 2012Applicant: Reckitt Benckiser LLCInventors: Nils Ahlgren, Mark Nuttall, Jeannie Wong, Venkatesh Balasubramanian, Craig Belongie, Ashfaq Khan, Neil Campbell Muir
-
Publication number: 20120184513Abstract: The invention relates to organic compounds having the ability to reduce or suppress the onset of skin irritation induced by extraneous cause selected from the group of 2-heptylcyclopentanone, 2-ethoxynaphthalene; 2-methoxynaphthalene; 1-methoxy-4-(prop-1-enyl)benzene; 1-(cyclopropylmethyl)-4-methoxybenzene; wherein X, Y, and R1 to R11 have the same meaning as given in the description. Furthermore the invention refers to compositions for topical application to the skin comprising them. It further relates to a method of reducing or suppressing the formation of skin irritation.Type: ApplicationFiled: January 14, 2011Publication date: July 19, 2012Applicant: Givaudan SAInventors: Andreas NATSCH, Michael WASESCHA
-
Publication number: 20120177725Abstract: The present invention relates to liposomal pharmaceutical preparations which include active agents such as antiseptic agents, wound-healing agents, or combinations thereof, useful in the treatment of external wounds. The active agents are encapsulated in liposomes, and the liposomes are incorporated in pharmaceutical preparations such as liquids, ointments, gels, lotions, or creams capable of delivering the active agents to external wound sites. The invention further relates to methods of preparation of the liposomes and the pharmaceutical preparations, and to methods of treatment of external wounds and ophthalmic infections.Type: ApplicationFiled: March 9, 2012Publication date: July 12, 2012Inventors: Dieter Ruckert, Hermann Gumbel, Wolfgang Fleischer, Karen Reimer, Horst Winkler
-
Publication number: 20120148520Abstract: The present inventions relate to a number of fields including wound healing, a waterless antibacterial disinfectant, a surgical scrub, insect repellant, and methods of treating traumatic injuries, particularly those on the battlefield where there is a need to stabilize the patient and prevent infection.Type: ApplicationFiled: December 9, 2011Publication date: June 14, 2012Inventors: Michael Strobel, Gene Komer
-
Publication number: 20120101085Abstract: The present teachings provide compounds of Formulae I and II: and pharmaceutically acceptable salts, hydrates, complexes, esters, and prodrugs thereof, wherein R1, R1?, R2, R2?, R3, R3?, and X are as defined herein. The present teachings also provide methods of making the compounds of formulae I and II, and methods of treating RyR-associated conditions, disorders, and diseases that include administering a therapeutically effective amount of a compound of formula I or II to a subject in need thereof. In addition, the present teachings relate to methods of reducing the open probability of a ryanodine receptor, and methods of reducing Ca2+ release across a ryanodine receptor (e.g., into the cytoplasm of a cell), by contacting a compound of formula I or II with a ryanodine receptor.Type: ApplicationFiled: April 15, 2010Publication date: April 26, 2012Applicant: State of Oregon By and Through the State Board of Higher Education on Behalf of Portland State Univ.Inventors: Jonathan J. Abramson, Robert Michael Stongin
-
Publication number: 20120087961Abstract: The invention relates to agents which combat the hepatitus A virus, containing only minimal amounts of chlorine-containing and/or chlorine cleaving active ingredients, or none of said substances. The inventions also relates to the use of these agents and to a method for their production.Type: ApplicationFiled: September 22, 2011Publication date: April 12, 2012Applicant: ECOLAB USA INC.Inventors: Friedrich Von Rheinbaben, Holger Biering, Klaus-Peter Bansemir, Sabine Glaeser
-
Publication number: 20120087874Abstract: The present invention includes compositions for imparting a controlled-release warming sensation to the oral receptor areas of a user. The oral, controlled-release warming compositions include a warming agent and a hydrated or swollen food-grade polymer which forms a matrix with the warming agent. Also included are oral delivery systems for the warming compositions, methods for preparing same, and methods for imparting and sustaining a warming sensation in the mouth and upper portion of the gastrointestinal tract of the user.Type: ApplicationFiled: December 9, 2011Publication date: April 12, 2012Inventors: Jamileh Lakkis, Susan Pettigrew
-
Publication number: 20120053133Abstract: A novel antiseptic agent composition which has a wide antimicrobial spectrum and excellent antiseptic properties is provided. An antiseptic agent composition A contains a glycerin hydroxy fatty acid monoester that is an ester of glycerin and a hydroxy fatty acid having 8 to 18 carbon atoms, and a specific antiseptic agent such as an alkanediol. An antiseptic agent composition B contains the glycerin hydroxy fatty acid monoester and an aromatic antiseptic agent. An antiseptic agent composition C contains the glycerin hydroxy fatty acid monoester and a chelating agent.Type: ApplicationFiled: January 18, 2010Publication date: March 1, 2012Applicant: TAIYO CORPORATIONInventors: Shuji Kanatani, Soota Iwamoto
-
Patent number: 8106080Abstract: The present invention is directed to compounds, combinations, compositions and methods for enhancing nitric oxide (NO) delivery to target sites, and in particular to muscle, both normal and dystrophic. Enhanced NO delivery according to the present invention may be achieved by using a combination of a muscle relaxant and an NO donor compound, or by using a compound of the invention: formula (I) wherein R1 is H, halo, C1-6 alkoxy or C1-6 alkyl; R2 is H, NO2 or C(O)NH2; R3 is H, NO2 or C(O)NH2; and at least one of R2 and R3 is NO2; or a pharmaceutically acceptable salt of the compound.Type: GrantFiled: June 8, 2006Date of Patent: January 31, 2012Inventors: Gu-Qi Wang, Frank J Burczynski, Judith E Anderson
-
Publication number: 20120010299Abstract: The present invention is directed toward a method of administering an oral solution containing one or more active ingredients, preferably formulations for non-prescription medicines, vital fluids, and/or nutritional supplements, optimally dosed based upon a patient's weight. The method includes providing an oral solution having an effective amount of one or more active ingredients; determining the weight of the individual, preferably to an individual less than 12 years old; and administrating an appropriate amount of the oral solution in a single dose dispensing unit in accordance with the weight determination of the individual, whereby the total amount of active ingredient administered corresponds to an effective amount of the active ingredient based on the individual's weight.Type: ApplicationFiled: June 27, 2011Publication date: January 12, 2012Inventors: Brian Kaplan, Robert Terwilliger, Richard Haskins, Paul Schlie
-
Publication number: 20120004310Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.Type: ApplicationFiled: May 27, 2011Publication date: January 5, 2012Inventors: Frank M. LONGO, Stephen M. Massa, Sandeep Gupta
-
Publication number: 20110312904Abstract: The present invention provides compounds of Formula (I), compositions comprising an effective amount of a compound of Formula (I), optionally with chemotherapeutic drugs such as a tubulin-binding drug, and methods of their use for reducing the toxicity of cytotoxic agents, treating or preventing cancer or a neuropathic disorder, inducing a chemoprotective phase II enzyme, DNA, or protein synthesis, enhancing the immune system, treating inflammation, improving and enhancing general health or well-being, and methods for making compounds of Formula (I).Type: ApplicationFiled: August 27, 2009Publication date: December 22, 2011Applicants: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Samuel J. Danishefsky, Ting-Chao Chou, Xiaoguang Lei, Heedong Yun, Fay Ng, John Hartung, Dalibor Sames
-
Publication number: 20110301105Abstract: We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells such as skin-derived precursors (SKPs)). The invention therefore invention provides compositions, methods, and kits for increasing proliferation of cells, using compounds that decrease p63 expression or activity or using the compounds described herein. The invention also features methods of using these compounds for increasing hair growth, improving skin health, or promoting skin repair in a subject.Type: ApplicationFiled: March 30, 2011Publication date: December 8, 2011Applicant: The Hospital for Sick ChildrenInventors: Freda Miller, David Kaplan, Kristen Smith, Maryline Paris, Sibel Naska
-
Publication number: 20110281892Abstract: Methods and dosage formulations for the safe treatment of cold, cough, flu, and sinus symptoms in children and adolescents by age and nature of symptoms, and adults and the elderly by age, nature of symptoms, and concomitant patient medical conditions. The method of the present invention comprises the formulation of a cold medication which consists essentially of combinations of a nonsedating or minimally sedating antihistamines with pain relievers and the expectorant, guaifenesin.Type: ApplicationFiled: May 16, 2011Publication date: November 17, 2011Inventor: Bernard Silverman
-
Patent number: 8057786Abstract: The present invention relates to cosmetic and/or dermatological compositions for the treatment of keratin containing substrates, comprising synergistic mixtures of modified starch polymers with defined molecular weights and cationic charges in a cosmetically acceptable medium. The synergistic mixtures of modified starches employed to manufacture compositions according to the present invention exhibit significant benefits over the existing modified starches employed according to the state-of-the-art in the treatment of keratin-containing substrates like human or animal hair, skin and nails. Another aspect of the present invention is the stabilization of the modified starch solutions used to manufacture the cosmetic and/or dermatological compositions according to the present invention against the growth of micro-organisms without traditional preservatives.Type: GrantFiled: March 6, 2009Date of Patent: November 15, 2011Assignee: Dr. Straetmans Chemische Produkte GmbHInventors: Kurt Dieker, Jan Jänichen, Wilfried Petersen, Manuela Salmina-Petersen, Michael Kinder, Jessica Scholze
-
Patent number: 8053477Abstract: Compounds that bind S100 and inhibit the S100-p53 protein-protein interaction and activate the tumor suppressor activity of p53, and thus which have an antineoplastic effect are disclosed, as well as methods for identifying these compounds, compositions comprising the same, and methods of using the same to treat cancer.Type: GrantFiled: March 27, 2003Date of Patent: November 8, 2011Assignee: University of Maryland, BaltimoreInventors: David J. Weber, Joseph Markowitz, France Carrier, Alexander D. MacKerell
-
Publication number: 20110229542Abstract: An antimicrobial fabric and method for treating fabric to impart antimicrobial properties thereto by preparing an aqueous solution of eugenol, polyvinyl alcohol, and glyoxal, padding the fabric with the aqueous solution to achieve a preselected desired part by weight wet pickup, drying the fabric; and curing the fabric.Type: ApplicationFiled: March 21, 2011Publication date: September 22, 2011Applicant: PHILADELPHIA UNIVERSITYInventors: Diana R. Cundell, Alexander A. Messinger, Brian R. George, Bhalchandra Dhamankar, Ekaterina Shumilova
-
Publication number: 20110218250Abstract: The invention relates to compositions which comprise one or more glycerol ethers together with one or more diol/diols and/or polyol/polyols. As a result, as well as good microbicidal effectiveness, whitening is reduced or avoided, drying-out of the skin is prevented, the moisture content is regulated and the skin is regreased to an adequate extent.Type: ApplicationFiled: May 20, 2011Publication date: September 8, 2011Applicant: AIR LIQUIDE SANTE (INTERNATIONAL)Inventors: WOLFGANG BEILFUSS, Sabine Wutsch, Klaus Weber, Ralf Gradtke
-
Publication number: 20110212933Abstract: The invention provides antiseptic compositions that comprise a wide spectrum antiseptic component (WSAC) and optionally one or more other active ingredients. The WSAC comprises an alcohol, one or more antimicrobial phenol compounds, one or more antimicrobial agents, a solvent and optionally, one or more non-ionic detergents. Additional components such as additional active agents, and thickeners can also be optionally added. The antiseptic compositions have a wide-spectrum of antiseptic activity against microorganisms and exhibit minimal toxicity and minimal irritation and can be used to treat and/or prevent dermal, mucosal, cuticle (such as nail or hoof) or genital infections in a patient.Type: ApplicationFiled: March 20, 2008Publication date: September 1, 2011Inventor: Allan Shapiro
-
Publication number: 20110165266Abstract: A method of screening test chemicals or compounds as inhibitors of HIV replication is disclosed. In one embodiment, the method comprises the step of determining whether the test chemical or compound is a sulfonation inhibitor. In another embodiment, the invention is a method of treating an HIV infected individual to reduce HIV replication comprising the step of treating the individual with an effective amount of sulfonation inhibitor.Type: ApplicationFiled: April 30, 2009Publication date: July 7, 2011Inventors: James W. Bruce, Paul G. Ahlquist, John A.T. Young
-
Publication number: 20110158920Abstract: A method for producing a bigel, the method comprising: (a) providing an oleogel comprising at least one oily agent gelled with at least one cellulose polymer; (b) providing an aqueous gel comprising at least one component whose viscosity is pH dependent, such as a carbomer; (c) mixing the oleogel and the aqueous gel together to form a bigel; and (d) subsequently adjusting the viscosity of the bigel under high flow and low shear stirring to obtain a bigel of a desired viscosity.Type: ApplicationFiled: December 31, 2007Publication date: June 30, 2011Applicant: ARDANA BIOSCIENCE LIMITEDInventors: Timothy Morley, Julian Robert Walker Fisher
-
Patent number: 7968606Abstract: The present invention provides a perfume composition, which comprises at least one trimethoxybenzene in an amount of less than 0.5% by weight based on the total weight of the perfume composition. The present invention also provides a method for providing sedation in a subject, which comprises applying a perfume composition comprising at least one trimethoxybenzene in an amount of less than 0.5% by weight based on the total weight of the perfume composition to the subject.Type: GrantFiled: June 30, 2006Date of Patent: June 28, 2011Assignee: Takasago International CorporationInventors: Jonathan Warr, Satomi Kunieda, Yoshiaki Numata
-
Publication number: 20110152372Abstract: Novel dermatological depigmentation compositions, especially for topical application, contain as pharmaceutical active agents a dissolved phenolic compound and a retinoid, formulated as anhydrous compositions free of petroleum jelly and free of elastomer. The present invention relates to a novel depigmenting composition especially for topical application, comprising as pharmaceutical active agents a dissolved phenolic derivative and a retinoid, in the form of an anhydrous composition free of petroleum jelly and free of elastomer, to the process for preparing it and to its use in dermatology.Type: ApplicationFiled: June 2, 2009Publication date: June 23, 2011Applicant: Galderma Research & DevelopmentInventors: Claire Mallard, Karine Nadau-Fourcade, Fabienne Louis
-
Publication number: 20110144213Abstract: Novel anhydrous dermatological depigmenting compositions, especially for topical application, contain, as pharmaceutical active agent, a phenolic compound dissolved in a fatty phase therefor.Type: ApplicationFiled: June 2, 2009Publication date: June 16, 2011Inventors: Claire Mallard, Karine Nadau-Fourcade, Fabienne Louis
-
Publication number: 20110144127Abstract: Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating glaucomatous retinopathy or optic neuropathy. The structurally diverse agents that act on the Nrf2/ARE pathway induce the expression of enzymes and proteins that possess chemically versatile cytoprotective properties and are a defense against toxic metabolites and xenobiotics. Agents include certain electrophiles and oxidants such as a Michael Addition acceptor, diphenol, thiocarbamate, quinone, 1,2-dithiole-3-thione, butylated hydroxyanisole, flavonoid, an isothiocyanate, 3,5-di-tert-butyl-4-hydroxytoluene, ethoxyquin, a coumarin, combinations thereof, or a pharmacologically active derivative or analog thereof.Type: ApplicationFiled: February 22, 2011Publication date: June 16, 2011Applicant: ALCON INC.Inventors: Robert A. Landers, Iok-Hou Pang
-
Publication number: 20110136669Abstract: The invention relates to continuous fiber layers comprising an active substance on the basis of bio-polymers, comprising a fibrous, bio-polymer active substance carrier, and at least one active substance associated with the carrier and releasable from the continuous fiber layer; to formulations comprising an active substance, said formulations comprising such continuous fiber layers; to the use of continuous fiber layers comprising an active substance for the production of formulations comprising an active substance; and to a method for the production of continuous fiber layers comprising an active substance. The invention further relates to corresponding continuous fiber layers comprising an active substance and to the use thereof for the production of wound treatment and hygiene products, and to the respectively produced wound treatment and hygiene products.Type: ApplicationFiled: August 7, 2009Publication date: June 9, 2011Applicant: BASF SEInventors: Burghard Liebmann, Evgueni Klimov
-
Publication number: 20110136851Abstract: The present invention is directed to a pharmaceutically acceptable taste masking liquid excipient base for administration of a relatively large amount of unpleasant tasting medicines. More particularly, the enhanced sweetness and taste masking effect are produced by the addition of sucralose to the excipient base with maintenance of a pH from about 2 to about 5. The invention is further directed to medicinal compositions comprising such a liquid excipient base and unpleasant tasting medicines. Still further, the invention is directed to a method for taste masking unpleasant tasting medicines through their incorporation into the claimed liquid excipient bases.Type: ApplicationFiled: February 1, 2011Publication date: June 9, 2011Applicant: Wyeth LLCInventors: David Jaeger, Jay Dickerson, Annabelle Trimmer
-
Publication number: 20110117048Abstract: Composition for application to skin comprising a biocide or combination of biocides (such as chlorhexidine, halogenated phenols, quaternary ammonium compounds; povidone-iodine; zinc pyridinethione; alcohols etc.) and at least one transcutaneous vehicle (for example alkyl methyl sulfoxides, alkyl pyrrolidones, glycols, glycol ethers and glycol esters) effective to convey the biocide to a sub epidermal “resident” micro-organism. Also a method for preparing a patient for surgery comprising the step of treating an area of the patient's skin at, and in the surrounding the vicinity of, the site of an intended surgical incision with a composition effective to kill more than 93% of both “transient” and “resident” micro-organisms.Type: ApplicationFiled: January 20, 2011Publication date: May 19, 2011Applicant: Novapharm Research (Australia) Pty Ltd.Inventor: Steven Kritzler
-
Publication number: 20110052689Abstract: The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1: 1) to about nine-to-one (9: 1), more preferably a range of about three-to-two (3:2) to about six-to-one (6: 1), and most preferably in a range of about two-to-one (2: 1) to about four-to-one (4: 1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin.Type: ApplicationFiled: November 5, 2010Publication date: March 3, 2011Applicant: RECKITT BENCKISER INC.Inventors: Robert D. Davis, Ralph W. Blume, Donald Jeffrey Keyser
-
Publication number: 20110054038Abstract: The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy/activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and/or released.Type: ApplicationFiled: August 20, 2010Publication date: March 3, 2011Applicant: TARGIA PHARMACEUTICALSInventor: Sabina Glozman
-
Patent number: 7897647Abstract: Activated polymeric bicine derivatives such as as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.Type: GrantFiled: August 9, 2006Date of Patent: March 1, 2011Assignee: Enzon Pharmaceuticals, Inc.Inventors: Hong Zhao, Richard B. Greenwald, Annapurna Pendri
-
Patent number: 7893304Abstract: The present invention provides compounds that are useful for preventing or treating brain dysfunctions, motor dysfunctions, or urinary dysfunctions caused by the degeneration and/or loss of the central nervous system or peripheral nervous system cells.Type: GrantFiled: February 23, 2006Date of Patent: February 22, 2011Assignee: Meiji Dairies CorporationInventors: Bang Luu, Dominique Bagnard, Mazen Hanbali, Masashi Yamada, Hiroto Suzuki
-
Publication number: 20110039874Abstract: Disclosed are compounds and compositions that inhibit the action of monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH), methods of inhibiting MGL and FAAH, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors.Type: ApplicationFiled: April 16, 2010Publication date: February 17, 2011Applicant: Northeastern UniversityInventors: Alexandros Makriyannis, Spyridon P. Nikas, Shakiru O. Alapafuja, Vidyanand G. Shukla
-
Publication number: 20110028542Abstract: A pharmaceutical composition for 1) increasing weight gain; and/or 2) decreasing weight loss; and/or 3) increasing appetite in a subject in need thereof, comprising purified ?-caryophyllene together with a pharmaceutically acceptable carrier. Also provided are pharmaceutical compositions for use in the prevention or treatment of Anorexia-Cachexia Syndrome, the pharmaceutical composition comprising purified ?-caryophyllene together with a pharmaceutically acceptable carrier.Type: ApplicationFiled: May 6, 2008Publication date: February 3, 2011Inventors: Jean Legault, Andre Pichette
-
Publication number: 20110021461Abstract: The present invention provides combinations of dietary supplements and methods of using of these combinations to improve the health and production performance of animals. In particular, the combinations of the invention comprise antioxidants, trace minerals, organic acids, essential amino acids, and mixtures thereof.Type: ApplicationFiled: December 30, 2008Publication date: January 27, 2011Applicant: NOVUS INTERNATIONAL INC.Inventors: Mercedes Vazquez-Anon, Gavin Bowman, Steven Andrew Webb, James Richards, Robert Harrell, Junmei Zhao, Megharaja K. Manangi
-
Publication number: 20100331426Abstract: Disinfectant which has activity towards mycobacteria and has (a) 1-(2-ethylhexyl} glycerol ether and (b) one or more aromatic alcohols group including aryloxyalkanols, ethers and arylalkanols.Type: ApplicationFiled: July 1, 2010Publication date: December 30, 2010Applicant: AIR LIQUIDE, SANTE (INTERNATIONAL)Inventors: Wolfgang BEILFUSS, Ralf GRADTKE, Wolfgang SIEGERT, Michael MOHR, Klaus WEBER
-
Publication number: 20100297059Abstract: The invention provides in part dialkoxybenzene and eugenol compounds for controlling infestation by a Lymantria dispar, and methods thereof. The compounds include a compound of Formula I: where R1 may be methyl, ethyl, propyl, n-butyl, isopentyl (3-methylbutyl) or allyl; R2 may be at positions 2, 3 or 4 and may be H, methyl, ethyl, propyl, n-butyl, isopentyl (3-methylbutyl) or allyl; and R3 may be optionally present at positions 2, 3 and 4, and is allyl; with the provisos that when R2 is at position 2, R3 if present is at position 3, or when R2 is at position 3, R3 if present is at positions 2 or 4, or when R2 is at position 4, R3 if present is at position 2; or of Formula II: where R1 may be methyl, ethyl, propyl, n-butyl, isopentyl (3-methylbutyl) or allyl; or mixtures thereof.Type: ApplicationFiled: April 7, 2010Publication date: November 25, 2010Applicant: Simon Fraser UniversityInventors: Erika Plettner, Yongmei Gong, Regine Gries
-
Publication number: 20100297215Abstract: Compositions, pharmaceutical preparations and methods are disclosed for protecting non-neoplastic cells from damage caused by cancer chemotherapeutic agents or radiation therapy, during the course of cancer therapy or bone marrow transplant. These are based on the use of chemoprotective inducing agents that induce or increase production of cellular detoxification enzymes in target cell populations. The compositions and methods are useful to reduce or prevent hair loss, gastrointestinal distress and lesions of the skin and oral mucosa that commonly occur in patients undergoing cancer therapy. Also disclosed is a novel assay system for identifying new chemoprotective inducing agents.Type: ApplicationFiled: May 11, 2009Publication date: November 25, 2010Inventors: William E. Fahl, Nalini Raghavachari, Ming Zhu, John A. Kink
-
Publication number: 20100249244Abstract: The presently claimed and disclosed inventive concept(s) contemplates compositions comprising compounds, in particular dihydroeugenol (DHE) and/or isoeugenol (IE) and/or ethyl vanillin (EV) or salts, esters, ethers, or derivatives thereof, and methods for topically or systemically delivering them for treatment against inflammation-related and other dermatological conditions such as described herein. These DHE and/or IE and/or EV or salts, esters, ethers or derivatives thereof also are delivered to a measurable extent transepidermally or transdermally.Type: ApplicationFiled: March 31, 2010Publication date: September 30, 2010Inventor: Bryan B. Fuller
-
Publication number: 20100247462Abstract: Processes for synthesizing resveratrol-based oligomers are provided. In addition, resveratrol-based oligomer compounds free of plant extract are provided.Type: ApplicationFiled: September 17, 2008Publication date: September 30, 2010Inventors: Scott Alan Snyder, Steven P. Breazzano, Audrey G. Ross, Yunqing Lin, Alexandros L. Zografos
-
Publication number: 20100233223Abstract: Provided herein are powder-free elastomeric articles exhibiting good antimicrobial and anti-blocking properties. Also provided herein are methods for the manufacture of such articles substantially free from antimicrobial interfering materials, as well as packaging means for maintaining antimicrobial efficacy.Type: ApplicationFiled: March 9, 2010Publication date: September 16, 2010Applicant: Ansell LimitedInventors: Aik Hwee Eng, Hee Meng Lai, Kuang Leng Lim, Koon Meow Ting, David M. Lucas
-
Publication number: 20100227009Abstract: The present invention is directed to pest-controlling compositions comprising as active ingredients one or more ?-diones, particularly ?-diketones and ?-triketones, and to the use of these compositions inter alia for preventing, eradicating, destroying, repelling or mitigating harmful, annoying or undesired pests including insects, arachnids, helminths, molluscs, protozoa and viruses. The present invention is further directed to processes of preparing ?-diones by de novo synthesis or from natural sources such as volatile oil-bearing plants from families including Alliaceae, Apiaceae, Asteraceae, Cannabinaceae, Lamiaceae, Pteridaceae, Myrtaceae, Myoporaceae, Proteaceae, Rutaceae and Zingiberaceae.Type: ApplicationFiled: May 18, 2010Publication date: September 9, 2010Applicants: BIOPROSPECT LIMITED, UNIVERSITY OF WESTERN SYDNEYInventors: Robert Neil Spooner-Hart, Albert Habib Basta
-
Publication number: 20100215774Abstract: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin and/or other active drugs through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.Type: ApplicationFiled: February 8, 2008Publication date: August 26, 2010Inventor: Todd Maibach
-
Publication number: 20100204244Abstract: Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating diabetic retinopathy or drusen formation in age-related macular degeneration. The structurally diverse agents that act on the Nrf2/ARE pathway induce the expression of enzymes and proteins that possess chemically versatile cytoprotective properties and are a defense against toxic metabolites and xenobiotics. Agents include certain electrophiles and oxidants such as a Michael Addition acceptor, diphenol, thiocarbamate, quinone, 1,2-dithiole-3-thione, butylated hydroxyanisole, flavonoid other than genistein, an isothiocyanate, 3,5-di-tert-butyl-4-hydroxytoluene, ethoxyquin, a coumarin, combinations thereof, or a pharmacologically active derivative or analog thereof.Type: ApplicationFiled: March 2, 2010Publication date: August 12, 2010Applicant: ALCON INC.Inventors: Robert A. Landers, David P. Bingaman
-
Publication number: 20100197803Abstract: The method for obtaining a sequoyitol-containing extract from a plant of the genus of Trifolium, Leguminosae or Ginkgoaceae, an extract obtained by the method and the use of the extract for the preparation of medicaments for treating diabetes and its complications, the method comprises the steps of extracting with a solvent, recovering the solvents to give an extractum, subjecting the extractum to two-phase extraction and column chromatography, collecting the fractions containing sequoyitol, concentrating, filtration and drying.Type: ApplicationFiled: May 28, 2008Publication date: August 5, 2010Applicant: LIANCHUANGSIYUANLI BIOLOGY AND SCIENCE AND TECHNOLOGY CO., LTDInventors: Tianyu Sun, Yanli Wang, Guixing Deng, Yinyin Wang, You Lu, Ting Wang
-
Publication number: 20100184858Abstract: The progression of hepatic fibrosis and hepatic cirrhosis caused by various hepatic disorders and damages such as chronic hepatitis can be restrained by hepatic fibrosis inhibitor containing a compound represented by the following chemical formula: wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6, or alkoxycarbonyl group with a carbon number of 2 to 6.Type: ApplicationFiled: December 7, 2009Publication date: July 22, 2010Inventors: Naohisa Ishikawa, Satoru Sugiyama, Tokutaro Miki, Hiroshi Nishikawa
-
Publication number: 20100166726Abstract: Methods and compositions that increase the cellular uptake of a chemotherapeutic agent are provided. Also provided are methods of increasing access to the cell surface by antibodies and ligands. The methods are useful in treating any mucinous carcinoma characterized by an increased expression and/or secretion of mucins. In addition, these methods provide an improvement in existing methods of chemotherapy.Type: ApplicationFiled: March 7, 2008Publication date: July 1, 2010Applicant: NORTHEASTERN UNIVERSITYInventor: Robert B. Campbell
-
Publication number: 20100160451Abstract: The invention provides in part dialkoxybenzene compounds for controlling infestation by a Trichoplusia ni, and methods thereof. The compounds include a compound of Formula I: where R1 may be methyl, ethyl, propyl, n-butyl, isopentyl(3-methylbutyl) or allyl; R2 may be at positions 2, 3 or 4 and may be H, methyl, ethyl, propyl, n-butyl, isopentyl(3-methylbutyl) or allyl; and R3 may be optionally present at positions 2, 3 and 4, and is allyl; except that when R2 is at position 2, R3 if present is at position 3, and when R2 is at position 3, R3 if present is at positions 2 or 4, and when R2 is at position 4, R3 if present is at position 2, and when R2 is at position 4 and R3, if present, has reacted with an OH group at position 1 in a Markovnikov sense, then R3 becomes R4, a dihydrofuran.Type: ApplicationFiled: November 19, 2009Publication date: June 24, 2010Applicants: Simon Fraser University, The University of British ColumbiaInventors: Erika Plettner, Murray Bruce Isman
-
Publication number: 20100160432Abstract: A compound is prepared based on Formula 1: wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6 or alkoxycarbonyl group with a carbon number of 2 to 6. A curative drug for neurodegenerative diseases can be prepared principally from the compound or a hydroquinone derivative consisting of a cyclodextrin inclusion compound thereof. The curative drug for neurodegenerative diseases has a safe and beneficial effect of inhibiting nerve cell disorder due to oxidative stress, thereby to stop progression of symptoms.Type: ApplicationFiled: February 24, 2010Publication date: June 24, 2010Inventors: Satoru Sugiyama, Tokutaro Miki, Hiroshi Nishikawa